Recursion Pharmaceuticals Inc (NASDAQ: RXRX) on Monday, soared 1.15% from the previous trading day, before settling in for the closing price of $6.11. Within the past 52 weeks, RXRX’s price has moved between $4.97 and $15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 132.77%. The company achieved an average annual earnings per share of 1.11%. With a float of $222.95 million, this company’s outstanding shares have now reached $226.26 million.
In terms of profitability, gross margin is -26.05%, operating margin of -824.25%, and the pretax margin is -767.94%.
Recursion Pharmaceuticals Inc (RXRX) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Recursion Pharmaceuticals Inc is 22.56%, while institutional ownership is 75.73%. The most recent insider transaction that took place on Oct 02 ’24, was worth 123,200. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $6.16, taking the stock ownership to the 762,656 shares. Before that another transaction happened on Oct 03 ’24, when Company’s Chief Executive Officer sold 20,000 for $6.08, making the entire transaction worth $121,600. This insider now owns 762,656 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 1.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Recursion Pharmaceuticals Inc (RXRX) is currently performing well based on its current performance indicators. A quick ratio of 6.07 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 35.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.62, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.72 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
The latest stats from [Recursion Pharmaceuticals Inc, RXRX] show that its last 5-days average volume of 4.74 million was inferior to 5.84 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 6.32%. Additionally, its Average True Range was 0.36.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 6.17%, which indicates a significant decrease from 10.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.73% in the past 14 days, which was lower than the 72.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.81, while its 200-day Moving Average is $8.95. Now, the first resistance to watch is $6.24. This is followed by the second major resistance level at $6.29. The third major resistance level sits at $6.40. If the price goes on to break the first support level at $6.08, it is likely to go to the next support level at $5.97. The third support level lies at $5.92 if the price breaches the second support level.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
Market capitalization of the company is 1.78 billion based on 237,664K outstanding shares. Right now, sales total 44,580 K and income totals -328,070 K. The company made 14,420 K in profit during its latest quarter, and -97,540 K in sales during its previous quarter.
